Article

Weighing the Value of Clinical Decision Support Tools

A study from the RAND corporation, published in JAMA, found clinical decision support tools increased the proportion of tests for Medicare fee-for-service patients rated as appropriate.

The Protecting Access to Medicare Act of 2014 passed by Congress made it mandatory for institutions to use appropriate clinical decision support (CDS) tools to qualify for Medicare reimbursement. Additionally, CDS is also a part of Stage 2 Meaningful Use requirements for electronic medical records. The hope was that CDS would help reduce healthcare spending associated with unnecessary and expensive imaging such as MRI and CT scans.

However, a recent study from the RAND corporation, published in JAMA, found that these computer-based programs that match a patient's characteristics against treatment criteria and recommend a treatment, actually increased the proportion of tests for Medicare fee-for-service patients rated as appropriate. "In our full report to Congress, we've outlined a series of improvements to the decision support tools that we expect can lead to greater reductions in unnecessary tests," siad Peter S. Hussey, lead author of the study and a senior policy researcher at RAND.

Read more on ScienceDaily: http://bit.ly/1JlxtO1

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Hamlet Gasoyan, PhD
EHA 2025 Congress Recap | Image Credit: Venngage
Ashley Yocum, PhD
Dr Matthew Matasar
Dr Xavier Leleu
Dr Marina Kremskayana
Dr Sundar Jagannath
5 experts are featured in this series
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo